首页|期刊导航|Pharmacoeconomics and Policy|Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic Evaluations

Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic Evaluations

Jing Wu Gordon G.Liu

Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.1-3,3.

Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.1-3,3.DOI:10.1016/j.pharp.2026.03.003

Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic Evaluations

Jing Wu ¹Gordon G.Liu²

作者信息

1. School of Pharmaceutical Science and Technology,Faculty of Medicine,Tianjin University,Tianjin 300072,China Institute of Health Economics and Policy,Tianjin University,Tianjin 300072,China Center for Social Science Survey and Data,Tianjin University,Tianjin 300072,China
2. Institute for Global Health and Development,Peking University,Beijing 100871,China National School of Development,Peking University,Beijing 100871,China
折叠

摘要

关键词

evidence based healthcare/national reimbursement drug list nrdl/innovative drugs/price negotiations/pharmacoeconomic evaluations/China guidelines/standardization

分类

医药卫生

引用本文复制引用

Jing Wu,Gordon G.Liu..Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic Evaluations[J].Pharmacoeconomics and Policy,2026,2(1):P.1-3,3.

基金项目

supported by the Major Project of the National Social Science Fund of China(Grant No.:25&ZD143). （Grant No.:25&ZD143）

Pharmacoeconomics and Policy

ISSN：2950-2667

访问量0

下载量0

段落导航